Enliven Therapeutics, Inc. (NASDAQ:ELVN) appears in 126 institutional 13F filings for the quarter ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 31 Mar, 2026 | 7,959,538 | 0 | 0.00% | $312,013,890.00 |
| ORBIMED ADVISORS LLC | 31 Mar, 2026 | 7,959,538 | 0 | 0.00% | $122,576,885.00 |
| FMR LLC | 31 Mar, 2026 | 7,107,635 | -21,561 | -0.30% | $109,457,572.00 |
| FMR LLC | 31 Mar, 2026 | 6,829,246 | -278,389 | -3.92% | $267,706,443.00 |
| Polar Capital Holdings Plc | 31 Mar, 2026 | 5,065,933 | 1,552,253 | 44.18% | $198,584,574.00 |
| Commodore Capital LP | 31 Mar, 2026 | 4,692,809 | 0 | 0.00% | $72,269,259.00 |
| Vestal Point Capital, LP | 31 Mar, 2026 | 3,830,000 | 2,670,000 | 230.17% | $58,982,000.00 |
| Fairmount Funds Management LLC | 31 Mar, 2026 | 3,711,444 | 0 | 0.00% | $57,156,238.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 3,684,707 | 71,381 | 1.98% | $144,440,514.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 3,613,326 | 94,802 | 2.69% | $55,645,219.00 |
| Polar Capital Holdings Plc | 31 Mar, 2026 | 3,513,680 | 418,673 | 13.53% | $54,110,672.00 |
| Commodore Capital LP | 31 Mar, 2026 | 3,275,000 | -1,417,809 | -30.21% | $128,380,000.00 |
| Vestal Point Capital, LP | 31 Mar, 2026 | 3,250,000 | -580,000 | -15.14% | $127,400,000.00 |
| VR Adviser, LLC | 31 Mar, 2026 | 3,226,331 | 0 | 0.00% | $49,685,497.00 |
| VANGUARD GROUP INC | 31 Mar, 2026 | 2,801,665 | 248,651 | 9.74% | $43,145,640.00 |
| Bellevue Group AG | 31 Mar, 2026 | 2,320,867 | 2,320,867 | 0.00% | $90,977,986.00 |
| Fairmount Funds Management LLC | 31 Mar, 2026 | 1,855,644 | -1,855,800 | -50.00% | $72,741,245.00 |
| CITADEL ADVISORS LLC | 31 Mar, 2026 | 1,743,915 | 319,571 | 22.44% | $68,361,468.00 |
| Venrock Adviser, LLC | 31 Mar, 2026 | 1,726,331 | -1,500,000 | -46.49% | $67,672,175.00 |
| Janus Henderson Group Plc | 31 Mar, 2026 | 1,671,724 | -121,859 | -6.79% | $25,744,550.00 |